Novo Nordisk and Eli Lilly have lowered the prices of their top-selling obesity drugs Wegovy and Mounjaro in China, according to statements from the Danish drugmaker and Chinese pharmaceutical suppliers.

Novo Nordisk did not disclose the new official pricing, but Chinese business news outlet Yicai reported earlier that list prices for the two highest doses of Wegovy had been reduced by about 48% in some provinces. The monthly prices were cut to around 987 yuan ($141) and 1,284 yuan respectively, the report said.